Search results for: 'study fe tech'

This Frost Radar on the global 3D modeling and animation software industry analyzes providers developing, selling, and supporting tools to create and manipulate 3D objects and animation for a variety of verticals and use cases, including media and entertainment (M&E), architecture, industrial design, and retail and marketing. These providers can o...

The modern threat landscape has undergone a profound transformation, driven by the global push toward digitalization. This has led to expanded attack surfaces, heightened IT complexity, and increased risks in supply chains. Today, threat actors launch multivector attacks that target organizations internal networks and their external digital assets...

A major challenge in drug discovery is the limited number of gene targets that can be targeted for the development of a drug molecule. Only close to 400 genes are proven targets for US FDA-approved drugs. 80% of human genes are unexplored as targets, and some are considered undruggable. The identification and the selection of novel drug targets (p...

The Frost Radar for the global medical virtual reality (VR) market analyzes providers developing tailored VR software solutions for medical and surgical training and education via simulated environments. From the vast array of medical simulations market, Frost & Sullivan has focused on medical VR software providers that offer fully immersive se...

Supply chain in any organization is literally its backbone. Cutting across a range of functions, it traverses across the life cycle of a product. Even a slight impediment can affect the entire value chain, run schedules off track, and significantly hamper productivity and efficiency. As companies struggle with visibility and transparency in the tra...

In 2003, the first human genome sequence was produced, with a production cost between $500 million and $1 billion. However, since 2008, when next-generation sequencing (NGS) approaches entered the research setting, there has been a significant decline in sequencing costs. These approaches allow either the whole genome (via whole-genome sequencing [...

The global CGT therapeutics market is transitioning from a niche, high-complexity segment into a mainstream, high-growth therapeutic class. Driven by scientific breakthroughs, accelerated regulatory pathways, and the entry of next-generation platforms—including in vivo CRISPR gene editing, allogeneic “off-the-shelf” cell therapies, and automated sm...

Pharmaceutical drug discovery and development processes suffer from declining success rates and a stagnant pipeline. Artificial Intelligence (AI) supported by Big Data could be a key element that can provide an effectual solution. There has been a rapid growth in the data generated within the life sciences and pharmaceutical industries. This stems ...